Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
(2007) 8-(3-(R)-Aminopiperidin-1-Yl)-7-But-2-Ynyl-3-Methyl-1-(4-Methyl-Quinazolin-2-Ylmethyl)-3,7-Dihydropurine-2,6-Dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Selected recent literature for research reference: Dehghanipour M et al
By April 2026, President Trump had announced 17 MFN deals covering the 17 leading pharmaceutical manufacturers, representing 86% of the branded drug market
The industry players are inclined to adopt various market strategies, such as new product launches, development of GLP-1 and dual agonist therapies, and strategic partnerships with telehealth platforms, to strengthen their market presence and gain maximum market share
Plasma levels of hepatotoxic makers such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as albumin concentration, were comparable among tested groups, indicating no significant safety concerns, despite the higher occurrence of knockout over knock-in events (Fig
:format(webp))
US$ 20.61
US$ 26.89
US$ 27.20
